California State Teachers Retirement System increased its position in shares of OvaScience Inc. (NASDAQ:OVAS) by 32.5% during the second quarter, Holdings Channel reports. The fund owned 65,828 shares of the company’s stock after buying an additional 16,144 shares during the period. California State Teachers Retirement System owned about 0.24% of OvaScience worth $343,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the stock. Northern Capital Management LLC increased its stake in OvaScience by 61.0% in the second quarter. Northern Capital Management LLC now owns 30,340 shares of the company’s stock worth $158,000 after buying an additional 11,500 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in OvaScience during the second quarter worth about $164,000. Trellus Management Company LLC bought a new stake in OvaScience during the second quarter worth about $208,000. FNY Managed Accounts LLC bought a new stake in OvaScience during the second quarter worth about $208,000. Finally, Stoneridge Investment Partners LLC increased its stake in OvaScience by 120.4% in the second quarter. Stoneridge Investment Partners LLC now owns 49,960 shares of the company’s stock worth $260,000 after buying an additional 27,291 shares during the last quarter. Institutional investors own 80.70% of the company’s stock.
OvaScience Inc. (NASDAQ:OVAS) traded down 5.53% during mid-day trading on Friday, reaching $6.32. 311,968 shares of the company’s stock traded hands. The company’s market capitalization is $224.75 million. The company has a 50-day moving average of $7.08 and a 200-day moving average of $7.06. OvaScience Inc. has a 52-week low of $4.53 and a 52-week high of $15.39.
OvaScience (NASDAQ:OVAS) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. OvaScience had a negative net margin of 13,906.35% and a negative return on equity of 60.10%. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. During the same quarter in the prior year, the business posted ($0.64) EPS. OvaScience’s quarterly revenue was up 530.0% on a year-over-year basis. Equities research analysts expect that OvaScience Inc. will post ($2.66) EPS for the current year.
A number of brokerages have recently weighed in on OVAS. JPMorgan Chase & Co. dropped their price objective on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Zacks Investment Research raised shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $10.31.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Want to see what other hedge funds are holding OVAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OvaScience Inc. (NASDAQ:OVAS).
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.